Pomalidomide

1. Pomalidomide decreases CD45RO+ CD27+ CD4+ T cells in humans.

   “a decrease in CD45RO - CD27 - (effector) CD4 + cells ( P = 0.0002)”

   Human trialin patients with Kaposi sarcoma5 mg3 cyclesn = 19

   Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration

   AIDS (London, England)·Jun 19, 2023

2. Pomalidomide increases CD45RO+ CD27+ CD4+ T cells in humans.

   “After three cycles, pomalidomide led to an increased proportion of CD45RO + CD27 + (central memory) CD4 + ( P = 0.002) and CD8 + ( P = 0.002) T cells”

   Human trialin patients with Kaposi sarcoma5 mg3 cyclesn = 19

   Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration

   AIDS (London, England)·Jun 19, 2023

More on CD45RO+ CD27+ CD4+ T cells

1. Pomalidomide increases immune response in humans.

   “expansion of CD38 + /HLADR + (activated) CD4 + ( P = 0.002) and CD8 + ( P ≤ 0.0001) T cells.”

   Human trialin patients with Kaposi sarcoma5 mg3 cyclesn = 19

   Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration

   AIDS (London, England)·Jun 19, 2023

More on Immune response

1. Pomalidomide decreases cellular senescence in humans.

   “After three cycles and at end-of-treatment, there was reduction in the proportion of CD57 + (senescent) CD4 + ( P = 0.001, 0.0006), and CD8 + ( P = < 0.0001, 0.0004) T cells.”

   Human trialin patients with Kaposi sarcoma5 mg3 cyclesn = 19

   Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration

   AIDS (London, England)·Jun 19, 2023

More on Cellular senescence